Clinical Trials Study
Copyright ©The Author(s) 2017.
World J Gastroenterol. Apr 21, 2017; 23(15): 2771-2784
Published online Apr 21, 2017. doi: 10.3748/wjg.v23.i15.2771
Figure 9
Figure 9 Receiver operating characteristic curves for 3-indoleacetic acid, indoleacetic acid, L-carnitine, and pyroglutamic acid in the non-alcoholic steatohepatitis and non-alcoholic fatty liver disease groups. NAFLD: Non-alcoholic fatty liver disease; NASH: Non-alcoholic steatohepatitis.